The IUSM‐Purdue Alzheimer's Disease Drug Discovery Center: A member of the NIH‐funded TREAT‐AD consortium: Nonhuman/Novel screening strategies. (7th December 2020)

• Record Type: Journal Article
• Authors: Palkowitz, Alan David; Lamb, Bruce T.; Oblak, Adrian L.; Reeves, Cristian A. Lasagna; Territo, Paul R.; Rizzo, Stacey J. Sukoff
• Is Part Of: Alzheimer's & dementia. Volume 16(2020)Supplement 9
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-07
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.041107
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: The T a r get E nablement to A dvance T herapeutics for A lzheimer's D isease (TREAT‐AD) Consortium is a newly formed NIA initiative designed to accelerate the discovery of new medicines for Alzheimer's Disease. It is comprised of two drug discovery centers: OPEN‐AD and the Indiana University School of Medicine‐Purdue University Alzheimer's Disease Drug Discovery Center (IUSM‐Purdue ADDD Center). The strategic goal of the consortium is to integrate sophisticated capability for early drug discovery and contribute to a broad study of emerging Alzheimer's Disease target hypotheses to create new classes of potential therapeutics. Method: The TREAT‐AD consortium will establish itself as a strategic and operational partner for the NIA‐Funded AMP‐AD, MODEL‐AD other AD directed translational research programs. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP‐AD) with newly discovered molecules characterized in next generation AD animal models based on human pathology, genetics and translational biomarkers (MODEL‐AD). Additionally, the TREAT‐AD consortium will make all data and research tools available to the scientific community to catalyze new research efforts. Result: The IUSM‐Purdue ADDD Center has assembled a world‐class team of scientists and capabilities that will pursue a research strategy focusing on neuro‐immune pathways implicated in Alzheimer's Disease with the following aims: Create a dynamic portfolio of well characterized AD drug discovery targets representing novel intervention hypotheses that capitalizes on significant investments in basic research and emerging disease understanding. Perform advanced pre‐clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. Create high quality and well characterized Lead molecules for prioritized targets that meet rigorous milestone criteria and are valued opportunities for further translational investment. Create a robust and flexible data sharing platform to enable global researchers with data and Target Enablement Packages to expand on the work of the Center. Conclusion: This presentation will provide an overview of the TREAT‐AD Consortium and the scientific strategy and plans for the IUSM‐Purdue ADDD Center.